Table 2.
Patient-reported indices of the study subjects
| Variable | Good sleeper (n = 62) | Poor sleeper (n = 53) | p value |
|---|---|---|---|
| EQ-5D score | 0.79 (0.70–1.00) | 0.69 (0.62–0.75) | 2.14 × 10–4 |
| Overall oral dryness VAS | 46.0 (9.5–73.0) | 60.0 (22.5–80.0) | 0.128 |
| Nocturnal oral dryness VAS | 20.0 (6.0–62.5) | 40.0 (5.0–70.0) | 0.757 |
| XI score | 34 (25–45) | 41 (29–47) | 0.098 |
| Overall eye dryness VAS | 40.0 (8.0–69.3) | 60.0 (22.2–80.0) | 0.044 |
| Eyeball pain VAS | 10.0 (0–40) | 20.0 (2.0–70.0) | 0.176 |
| OSDI score | 20.8 (10.4–31.3) | 23.0 (13.5–41.7) | 0.100 |
| ESS | 5.0 (2.9–5.7) | 6.0 (5.0–7.3) | 0.013 |
| Arthralgia VAS | 10.0 (0.0–28.0) | 40 (4.5–60.0) | 0.005 |
| Myalgia VAS | 10.0 (0.0–29.0) | 20.0 (1.0–60.0) | 0.055 |
| Anxiety VAS | 2.5 (0.0–20.0) | 10.0 (0.0–54.0) | 0.037 |
| PGA VAS | 10.0 (2.8–40.0) | 49.0 (20.0–70.0) | 4.99 × 10–4 |
| PSQI score | 6.0 (3.0–7.3) | 12.0 (10.0–15.0) | 2.31 × 10–20 |
| FSS score | 2.56 (1.78–4.50) | 4.56 (3.06–5.78) | 2.64 × 10–4 |
| FSS score ≥ 4 | 19 (30.6) | 30 (56.6) | 0.005 |
| BDI-II score | 7.5 (4.0–12.3) | 15.0 (7.5–21.5) | 6.42 × 10–5 |
| BDI-II score ≥ 14 | 14 (22.6) | 30 (56.6) | 1.83 × 10–4 |
Values are presented as median (interquartile range) or number (%). p values by the Mann-Whitney or chi-square test.
EQ-5D, EuroQol 5-dimensional questionnaire; VAS, visual analogue scale; XI, xerostomia inventory; OSDI, Ocular Surface Disease Index; ESS, European League Against Rheumatism (EULAR) sicca score; PGA, patient global assessment for Sjögren’s syndrome (SS); PSQI, Pittsburgh Sleep Quality Index; FSS, fatigue severity score; BDI, Beck Depression Inventory.